This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

The GFT505 study in NASH failed, analysts said. That's bad for Genfit and good for Intercept Pharmaceuticals, which is developing a rival drug for fatty liver known as OCA.
3/27/15 9:40AM
If history repeats itself, the recent weakness in biotech stocks will end with lots more buying.
3/26/15 7:17AM
In April, Celladon is expecting results from a mid-stage study of a gene therapy aiming to improve the pumping ability of the heart in patients with advanced heart failure.
3/25/15 10:06AM
Biotech CEOs are supposed to be cheerleaders for their stock, so it's noteworthy when a CEO's pocketbook indicates otherwise.
3/24/15 10:39AM
Biotech stocks may or may not be in a bubble, but investors are definitely worried about sky-high valuations.
3/24/15 8:56AM
Vertex disclosed some new phase IIb study results that raise concerns VX-661 may not be as potent as previously hoped.
3/23/15 9:07AM
Biogen shares are up on strong Alzheimer's drug data, but is the biotech bull market making investors forget about risk?
3/20/15 12:29PM
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
3/20/15 7:18AM
Biogen Idec's drug BIIB037 slowed cognitive decline and reduced brain plaques in Alzheimer's patients.
3/20/15 6:40AM
Amicus will seek accelerated approval in the U.S. for its Fabry disease therapy in the second half of the year -- sooner than many investors expected.
3/19/15 7:41AM
Celgene will be starting phase III studies of mongersen in Crohn's disease -- designed to lead to the drug's approval -- by the middle of the year.
3/18/15 5:00PM
MannKind is facing a cash shortfall unless it can settle with debt holders by August.
3/18/15 9:17AM
When a biotech CEO diverts from safe, bland corporate tweets to engage in some clever competitive trolling, I stand and applaud.
3/17/15 10:26AM
Biogen has added $25 billion in market value since the December -- a sign investors are willing to believe BIIB037 might succeed where several other similar Alzheimer's drugs have failed.
3/16/15 12:15PM
The cross-trial comparison between CTI BioPharma's pacritinib and Incyte's Jakafi looks worse than expected.
3/13/15 9:36AM
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
3/13/15 9:00AM
Neuralstem is providing an overly optimistic picture about its surgical stem-cell therapy for amyotrophic lateral sclerosis (ALS), the degenerative and fatal nerve disease.
3/12/15 11:26AM
Biotech companies are experiencing an unprecedented run of scientific successes, but biotech stock valuations have never been more expensive.
3/12/15 9:25AM
Acadia admits that it can't seek approval for its Parkinson's psychosis drug this quarter, as promised. The company's CEO also resigned.
3/11/15 4:39PM
Skin cancer patients in Britain can be treated with Merck's Keytruda before the cancer immunotherapy drug is approved there under a new early access plan announced Wednesday.
3/11/15 10:45AM
It won't be easy to compare the phase II trail results from Genfit and Intercept's competing NASH drugs, but understanding the differences in their respective clinical trials should help.
3/11/15 9:58AM
Since the end of September, Hemispherx sold almost 25 million shares of company stock, equivalent to the amount of stock sold in the first nine months of 2014.
3/10/15 11:10AM
Ocular hasn't conducted clinical trials that would demonstrate that OTX-DP is any better than eye drops in reducing swelling and pain in the eye.
3/10/15 10:17AM
CTI Biopharma's experimental drug pacritinib significantly reduced the spleen size in patients with myelofibrosis compared to patients treated with best alternative care.
3/9/15 8:15AM

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs